$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

상세검색 다국어 입력
도움말도움말
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

MyON담기
내보내기

Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways

Oncotarget v.9 no.4 , 2018년, pp.4301 - 4317  
Chae, Hee-Don (Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA ) ;  Cox, Nick ( Medicinal Chemistry Knowledge Center, Stanford ChEM-H, Stanford, CA, USA ) ;  Dahl, Gary V. ( Medicinal Chemistry Knowledge Center, Stanford ChEM-H, Stanford, CA, USA ) ;  Lacayo, Norman J. ( Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA ) ;  Davis, Kara L. ( Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA ) ;  Capolicchio, Samanta ( Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA ) ;  Smith, Mark ( Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA ) ;  Sakamoto, Kathleen M. ( Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA)
Abstract

CREB (cAMP Response Element Binding protein) is a transcription factor that is overexpressed in primary acute myeloid leukemia (AML) cells and associated with a decreased event-free survival and increased risk of relapse. We recently reported a small molecule inhibitor of CREB, XX-650-23, which inhibits CREB activity in AML cells. Structure-activity relationship analysis for chemical compounds with structures similar to XX-650-23 led to the identification of the anthelminthic drug niclosamide as a potent anti-leukemic agent that suppresses cell viability of AML cell lines and primary AML cells without a significant decrease in colony forming activity of normal bone marrow cells. Niclosamide significantly inhibited CREB function and CREB-mediated gene expression in cells, leading to apoptosis and G1/S cell cycle arrest with reduced phosphorylated CREB levels. CREB knockdown protected cells from niclosamide treatment-mediated cytotoxic effects. Furthermore, treatment with a combination of niclosamide and CREB inhibitor XX-650-23 showed an additive anti-proliferative effect, consistent with the hypothesis that niclosamide and XX-650-23 regulate the same targets or pathways to inhibit proliferation and survival of AML cells. Niclosamide significantly inhibited the progression of disease in AML patient-derived xenograft (PDX) mice, and prolonged survival of PDX mice. Niclosamide also showed synergistic effects with chemotherapy drugs to inhibit AML cell proliferation. While chemotherapy antagonized the cytotoxic potential of niclosamide, pretreatment with niclosamide sensitized cells to chemotherapeutic drugs, cytarabine, daunorubicin, and vincristine. Therefore, our results demonstrate niclosamide as a potential drug to treat AML by inducing apoptosis and cell cycle arrest through inhibition of CREB-dependent pathways in AML cells.

  

주제어

#niclosamide   #acute myeloid leukemia   #small molecule   #CREB   #combination  

참고문헌 (57)

  1. 1. 1 Kavanagh S Murphy T Law A Yehudai D Ho JM Chan S Schimmer AD Emerging therapies for acute myeloid leukemia: translating biology into the clinic JCI Insight 2017 2 10.1172/jci.insight.95679 
  2. 2. 2 Dohner H Weisdorf DJ Bloomfield CD Acute Myeloid Leukemia N Engl J Med 2015 373 1136 52 10.1056/NEJMra1406184 26376137 
  3. 3. 3 Saygin C Carraway HE Emerging therapies for acute myeloid leukemia J Hematol Oncol 2017 10 93 10.1186/s13045-017-0463-6 28420416 
  4. 4. 4 Frohling S Scholl C Gilliland DG Levine RL Genetics of myeloid malignancies: pathogenetic and clinical implications J Clin Oncol 2005 23 6285 95 10.1200/JCO.2005.05.010 16155011 
  5. 5. 5 Fialkow PJ Janssen JW Bartram CR Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy Blood 1991 77 1415 7 2009365 
  6. 6. 6 Crans-Vargas HN Landaw EM Bhatia S Sandusky G Moore TB Sakamoto KM Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia Blood 2002 99 2617 9 11895805 
  7. 7. 7 Mayr B Montminy M Transcriptional regulation by the phosphorylation-dependent factor CREB Nat Rev Mol Cell Biol 2001 2 599 609 10.1038/35085068 11483993 
  8. 8. 8 Siu YT Jin DY CREB—a real culprit in oncogenesis FEBS J 2007 274 3224 32 10.1111/j.1742-4658.2007.05884.x 17565603 
  9. 9. 9 Radhakrishnan I Perez-Alvarado GC Parker D Dyson HJ Montminy MR Wright PE Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator: coactivator interactions Cell 1997 91 741 52 9413984 
  10. 10. 10 Chrivia JC Kwok RP Lamb N Hagiwara M Montminy MR Goodman RH Phosphorylated CREB binds specifically to the nuclear protein CBP Nature 1993 365 855 9 10.1038/365855a0 8413673 
  11. 11. 11 Kwok RP Lundblad JR Chrivia JC Richards JP Bachinger HP Brennan RG Roberts SG Green MR Goodman RH Nuclear protein CBP is a coactivator for the transcription factor CREB Nature 1994 370 223 6 10.1038/370223a0 7913207 
  12. 12. 12 Haus-Seuffert P Meisterernst M Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB Mol Cell Biochem 2000 212 5 9 11108130 
  13. 13. 13 Shankar DB Cheng JC Kinjo K Federman N Moore TB Gill A Rao NP Landaw EM Sakamoto KM The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia Cancer cell 2005 7 351 62 10.1016/j.ccr.2005.02.018 15837624 
  14. 14. 14 Cheng JC Kinjo K Judelson DR Chang J Wu WS Schmid I Shankar DB Kasahara N Stripecke R Bhatia R Landaw EM Sakamoto KM CREB is a critical regulator of normal hematopoiesis and leukemogenesis Blood 2008 111 1182 92 10.1182/blood-2007-04-083600 17975014 
  15. 15. 15 Stein EM Tallman MS Emerging therapeutic drugs for AML Blood 2016 127 71 8 10.1182/blood-2015-07-604538 26660428 
  16. 16. 16 Siveen KS Uddin S Mohammad RM Targeting acute myeloid leukemia stem cell signaling by natural products Mol Cancer 2017 16 13 10.1186/s12943-016-0571-x 28137265 
  17. 17. 17 Mitton B Chae HD Hsu K Dutta R Aldana-Masangkay G Ferrari R Davis K Tiu BC Kaul A Lacayo N Dahl G Xie F Li BX Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells Leukemia 2016 30 2302 11 10.1038/leu.2016.139 27211267 
  18. 18. 18 Andrews P Thyssen J Lorke D The biology and toxicology of molluscicides, Bayluscide Pharmacol Ther 1982 19 245 95 6763710 
  19. 19. 19 Pearson RD Hewlett EL Niclosamide therapy for tapeworm infections Ann Intern Med 1985 102 550 1 3977200 
  20. 20. 20 Chen W Mook RA Jr Premont RT Wang J Niclosamide: Beyond an antihelminthic drug Cell Signal 2017 41 89 96 10.1016/j.cellsig.2017.04.001 28389414 
  21. 21. 21 WHO 2002 WHO Specifications and Evaluations for Public Health Pesticides: Niclosamide. World Health Organisation Geneva Available from: http://www.who.int/whopes/quality/en/Niclosamide.pdf 
  22. 22. 22 Al-Hadiya BM Niclosamide: comprehensive profile Profiles Drug Subst Excip Relat Methodol 2005 32 67 96 10.1016/S0099-5428(05)32002-8 22469082 
  23. 23. 23 Li Y Li PK Roberts MJ Arend RC Samant RS Buchsbaum DJ Multi-targeted therapy of cancer by niclosamide: A new application for an old drug Cancer Lett 2014 349 8 14 10.1016/j.canlet.2014.04.003 24732808 
  24. 24. 24 Moskaleva EY Perevozchikova VG Zhirnik AS Severin SE [Molecular mechanisms of niclosamide antitumor activity]. [Article in Russian] Biomed Khim 2015 61 680 93 10.18097/PBMC20156106680 26716739 
  25. 25. 25 Jin Y Lu Z Ding K Li J Du X Chen C Sun X Wu Y Zhou J Pan J Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res 2010 70 2516 27 10.1158/0008-5472.CAN-09-3950 20215516 
  26. 26. 26 Bolton EE Kim S Bryant SH PubChem3D: Similar conformers J Cheminform 2011 3 13 10.1186/1758-2946-3-13 21554721 
  27. 27. 27 Yan X Liao C Liu Z Hagler AT Gu Q Xu J Chemical Structure Similarity Search for Ligand-based Virtual Screening: Methods and Computational Resources Curr Drug Targets 2016 17 1580 5 26521773 
  28. 28. 28 Willett P Barnard JM Downs GM Chemical Similarity Searching Journal of Chemical Information and Computer Sciences 1998 38 983 96 10.1021/ci9800211 
  29. 29. 29 Burgess DJ Doles J Zender L Xue W Ma B McCombie WR Hannon GJ Lowe SW Hemann MT Topoisomerase levels determine chemotherapy response in vitro and in vivo Proc Natl Acad Sci U S A 2008 105 9053 8 10.1073/pnas.0803513105 18574145 
  30. 30. 30 Jiang H Pritchard JR Williams RT Lauffenburger DA Hemann MT A mammalian functional-genetic approach to characterizing cancer therapeutics Nat Chem Biol 2011 7 92 100 10.1038/nchembio.503 21186347 
  31. 31. 31 Jia J Zhu F Ma X Cao Z Li Y Chen YZ Mechanisms of drug combinations: interaction and network perspectives Nat Rev Drug Discov 2009 8 111 28 10.1038/nrd2683 19180105 
  32. 32. 32 Breitinger HG 2012 Drug Synergy – Mechanisms and Methods of Analysis, Toxicity and Drug Testing Acree PB InTech 
  33. 33. 33 Lazebnik YA Kaufmann SH Desnoyers S Poirier GG Earnshaw WC Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE Nature 1994 371 346 7 10.1038/371346a0 8090205 
  34. 34. 34 Ren X Duan L He Q Zhang Z Zhou Y Wu D Pan J Pei D Ding K Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway ACS Med Chem Lett 2010 1 454 9 10.1021/ml100146z 24900231 
  35. 35. 35 Nicolas E Golemis EA Arora S POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies Gene 2016 590 128 41 10.1016/j.gene.2016.06.031 27320729 
  36. 36. 36 Chae HD Mitton B Lacayo NJ Sakamoto KM Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA Leukemia 2015 29 1379 89 10.1038/leu.2014.350 25541153 
  37. 37. 37 Mitton B Hsu K Dutta R Tiu BC Cox N McLure KG Chae HD Smith M Eklund EA Solow-Cordero DE Sakamoto KM Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters Oncotarget 2016 7 8653 62 10.18632/oncotarget.7085 26840025 
  38. 38. 38 Lai Y Wei X Lin S Qin L Cheng L Li P Current status and perspectives of patient-derived xenograft models in cancer research J Hematol Oncol 2017 10 106 10.1186/s13045-017-0470-7 28499452 
  39. 39. 39 Weinstein HJ Mayer RJ Rosenthal DS Coral FS Camitta BM Gelber RD Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update Blood 1983 62 315 9 6575837 
  40. 40. 40 Fonseca BD Diering GH Bidinosti MA Dalal K Alain T Balgi AD Forestieri R Nodwell M Rajadurai CV Gunaratnam C Tee AR Duong F Andersen RJ Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling J Biol Chem 2012 287 17530 45 10.1074/jbc.M112.359638 22474287 
  41. 41. 41 Viatour P Merville MP Bours V Chariot A Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation Trends Biochem Sci 2005 30 43 52 10.1016/j.tibs.2004.11.009 15653325 
  42. 42. 42 Tang ZH Acuna UM Fernandes NF Chettiar S Li PK De Blanco EC Structure-Activity Relationship of Niclosamide Derivatives Anticancer Research 2017 37 2839 43 28551619 
  43. 43. 43 Chang YW Yeh TK Lin KT Chen WC Yao HT Lan SJ Wu YS Hsieh HP Chen CM Chen CT Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats Journal of Food and Drug Analysis 2006 14 329 33 
  44. 44. 44 Roos WP Thomas AD Kaina B DNA damage and the balance between survival and death in cancer biology Nat Rev Cancer 2016 16 20 33 10.1038/nrc.2015.2 26678314 
  45. 45. 45 Shimada M Okuzaki D Tanaka S Tougan T Tamai KK Shimoda C Nojima H Replication factor C3 of Schizosaccharomyces pombe, a small subunit of replication factor C complex, plays a role in both replication and damage checkpoints Mol Biol Cell 1999 10 3991 4003 10588638 
  46. 46. 46 Sancar A Lindsey-Boltz LA Unsal-Kacmaz K Linn S Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu Rev Biochem 2004 73 39 85 10.1146/annurev.biochem.73.011303.073723 15189136 
  47. 47. 47 Stoimenov I Helleday T PCNA on the crossroad of cancer Biochem Soc Trans 2009 37 605 13 10.1042/BST0370605 19442257 
  48. 48. 48 Prosperi E The fellowship of the rings: distinct pools of proliferating cell nuclear antigen trimer at work FASEB J 2006 20 833 7 10.1096/fj.05-5469hyp 16675840 
  49. 49. 49 Moldovan GL Pfander B Jentsch S PCNA, the maestro of the replication fork Cell 2007 129 665 79 10.1016/j.cell.2007.05.003 17512402 
  50. 50. 50 Maga G Hubscher U Proliferating cell nuclear antigen (PCNA): a dancer with many partners J Cell Sci 2003 116 3051 60 10.1242/jcs.00653 12829735 
  51. 51. 51 Parrilla-Castellar ER Arlander SJ Karnitz L Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex DNA Repair (Amst) 2004 3 1009 14 10.1016/j.dnarep.2004.03.032 15279787 
  52. 52. 52 Lu X Tan CK Zhou JQ You M Carastro LM Downey KM So AG Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta J Biol Chem 2002 277 24340 5 10.1074/jbc.M200065200 11986310 
  53. 53. 53 Fares I Chagraoui J Gareau Y Gingras S Ruel R Mayotte N Csaszar E Knapp DJ Miller P Ngom M Imren S Roy DC Watts KL Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal Science 2014 345 1509 12 10.1126/science.1256337 25237102 
  54. 54. 54 Pabst C Krosl J Fares I Boucher G Ruel R Marinier A Lemieux S Hebert J Sauvageau G Identification of small molecules that support human leukemia stem cell activity ex vivo Nat Methods 2014 11 436 42 10.1038/nmeth.2847 24562423 
  55. 55. 55 Bijnsdorp IV Giovannetti E Peters GJ Analysis of drug interactions Methods Mol Biol 2011 731 421 34 10.1007/978-1-61779-080-5_34 21516426 
  56. 56. 56 Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001 25 402 8 10.1006/meth.2001.1262 11846609 
  57. 57. 57 Li BX Xiao X Discovery of a small-molecule inhibitor of the KIX-KID interaction Chembiochem 2009 10 2721 4 10.1002/cbic.200900552 19810079 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

이 논문과 함께 이용한 콘텐츠

DOI 인용 스타일

"" 핵심어 질의응답